Abstracts tagged "Therapy, alternative"

Abstract Number: 2699 • ACR Convergence 2025
Cutaneous IgA Vasculitis: Emulation of a Target Trial from a European Multicentric Retrospective Study
Elena Biancamaria Mariotti¹, Boris Sorin², William Lutz³, Chloé Grolleau³, Thomas Bettuzzi⁴, Caterina Ricordi⁵, Santos Castañeda⁶, Luisa Herda⁷, Cord Sunderkotter⁷, Rodérau Outh⁸, Romain Paule⁹, Alexandra Audemard-Verger¹⁰, Marzia Caproni¹¹, Angelo Valerio Marzano¹², Pietro Quaglino¹³, Laura Atzori¹⁴, Julien Campagne¹⁵, Mehemt Erkan¹⁶, Nabil Belfeki¹⁷, Marijan Frkovic¹⁸, Nicolas Dupin¹⁹, Raphael Porcher²⁰, Marie Jachiet²¹ and Benjamin Terrier¹⁹, ¹University of Florence, Azienda USL Toscana Centro, Department of Dermatology, Florence, Firenze, Italy, ²Assistance Publique Hôpitaux de Paris, Paris, France, ³University Paris Cité, Hospital Saint Louis, Dermatology department, Paris, Paris, France, ⁴Université Paris Est Créteil Val de Marne, Hôpital Henri-Mondor (APHP), Service de dermatologie, EpiDermE, Paris, France, ⁵AUSL-IRCCS Reggio Emilia, Parma, Italy, ⁶Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ⁷Department of Dermatology and Venereology, Martin Luther University Halle-Wittenberg, Halle (Saale), Halle, Germany, ⁸Department of Internal Medicine, Centre Hospitalier de Perpignan, Perpignan, France., Clermont-Ferrand, France, ⁹Hospital Foch, Service de medicine interne, Suresnes, Paris, Suresnes, France, ¹⁰Department of Internal Medicine, Tours University Hospital, Tours, France., Tours, France, ¹¹University of Florence, Azienda USL Toscana Centro, Department of Dermatology, Florence, Florence, Italy, ¹²Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Milan, Italy, ¹³University of Turin, Department of Medical Sciences, Section of Dermatology, Turin, Torino, Italy, ¹⁴Dermatology Clinic, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Cagliari, Italy, ¹⁵Hospital Robert Schuman, Metz, France, ¹⁶Hacettepe University Faculty of Medicine Department of Pediatric Rheumatology Ankara, Türkiye, Ankara, Turkey, ¹⁷Head of the Internal Medicine and Clinical Immunology Department South Île de France Health Hospital Group, Melun Center, Melun, France, ¹⁸Division for clinical immunology and rheumatology, Department of pediatrics UHC Zagreb / School of Medicine Zagreb Croatia, Zagabria, Croatia, ¹⁹Cochin Hospital, Paris, France, ²⁰Université Paris Cité and Université Sorbonne Paris Nord, INSERM, INRAE, Center for Research in Epidemiology and StatisticS (CRESS), Paris, France, Paris, France, ²¹University Paris Cité, Hôpital Saint-Louis, Dermatology department, Paris, Paris, France
Background/Purpose: Immunoglobulin A vasculitis (IgAV) is a small vessel vasculitis marked by IgA, deposition, palpable purpura with lower body predilection and variable joints, kidney and…
Abstract Number: 0702 • ACR Convergence 2025
Effectiveness of Oral Anticoagulants in Precapillary Pulmonary Hypertension Associated with Systemic Sclerosis: a EUSTAR Cohort Study.
Nicola Farina¹, Silvia Bellando-Randone², hilde Bjørkekjær³, David Launay⁴, Patricia E. Carreira⁵, paolo airò⁶, Serena Guiducci⁷, Dilia Giuggioli⁸, Gabriela Riemekasten⁹, carmen-Pilar Simeón Aznar¹⁰, Christina Bergmann¹¹, Elise Siegert¹², Ivan Castellví¹³, Lesley Ann Saketkoo¹⁴, Jeska de Vries-Bouwstra¹⁵, Dr. Philipp Klemm¹⁶, ulf Müller-Ladner¹⁷, Alexandra Balbir- Gurman¹⁸, Vanessa Smith¹⁹, Florenzo Iannone²⁰, Luca Idolazzi²¹, Christopher Denton²², edoardo rosato²³, Britta Maurer²⁴, Yannick Allanore²⁵, Yoshiya Tanaka²⁶, elisabetta zanatta²⁷, Marie-Elise Truchetet²⁸, Masataka Kuwana²⁹, Mickaël MARTIN³⁰, Alberto Cauli³¹, Kamal Solanki³², Francesco Del Galdo³³, Ana Maria Gheorghiu³⁴, Branimir Anic³⁵, Gábor Kumánovics³⁶, Gonçalo Boleto³⁷, Kristofer Andréasson³⁸, Simona Rednic³⁹, Lorinda Chung⁴⁰, susana Oliveira⁴¹, marius cadar⁴², Francesco Paolo Cantatore⁴³, Carolina de Souza Müller⁴⁴, Vivien Hsu⁴⁵, Yair Levy⁴⁶, Gianluca Moroncini⁴⁷, Jörg Henes⁴⁸, Andra Balanescu⁴⁹ and Ellen De Langhe⁵⁰, ¹Department of Experimental and Clinical Medicine, Scleroderma Unit, Division of Rheumatology, University of Florence, Azienda Ospedaliera Universitaria Careggi, Florence, Italy. Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milan, Italy, Milan, Italy, ²University of Florence, Florence, Florence, Italy, ³Department of Rheumatology, Hospital of Southern Norway, Kristiansand, Norway, olso, Norway, ⁴Univ. Lille, Inserm, CHU Lille, Department of Internal Medicine and Clinical Immunology, Reference Center for Rare Autoimmune and Autoinflammatory diseases (CERAINOM), U¹²⁸⁶ - INFINITE - Institute for Translational Research in Inflammation, Lille, France. National Reference Center for Pulmonary Arterial Hypertension (Pulmotension), Lille, France, Lille Cedex, France, ⁵Hospital Universitario ¹² de Octubre, Madrid, Spain, ⁶Rheumatology and Clinical Immunology Unit, ASST Spedali Civili of Brescia, University of Brescia, Brescia, Italy, brescia, Italy, ⁷Department of Experimental and Clinical Medicine, Scleroderma Unit, Division of Rheumatology, University of Florence, Azienda Ospedaliera Universitaria Careggi, Florence, Italy, Pistoia, Italy, ⁸Scleroderma Unit, Rheumatology Unit, University Hospital of Modena and Reggio Emilia, Modena, Italy, Modena, Italy, ⁹University Clinic Schleswit-Holstein (UKSH), Lübeck, Germany, ¹⁰Hospital Universitario Vall d'Hebron Passeig, Department of Internal Medicine, Systemic Autoimmune Diseases Unit, Barcelona, Spain, Zaragoza, Spain, ¹¹Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ¹²Charité University Hospital, Department of Rheumatology, Berlin, Germany, Berlin, Germany, ¹³Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, barcelona, Spain, ¹⁴University Medical Center - Comprehensive Pulmonary Hypertension Center and ILD Clinic Programs // New Orleans Scleroderma and Sarcoidosis Patient Care & Research Centeris, New Orleans, LA, ¹⁵Leiden University Medical Center, Leiden, Netherlands, ¹⁶Kerckhoff-Klinik Bad Nauheim, Berlin, Germany, ¹⁷JLU Giessen, Campus Kerckhoff, Department of Rheumatology and Clinical Immunology Center, Bad Nauheim, Germany, Bad Nauheim, Germany, ¹⁸Rambam Health Care Campus, Rheumatology Institute, Haifa, Israel, israel, Israel, ¹⁹Ghent University Hospital, Gent, Belgium, ²⁰Rheumatology DiMePReJ, University of Bari, School of Medicine, Bari, Italy, Bari, Italy, ²¹Section of Rheumatology, Department of Medicine, University of Verona, Verona, Italy, verona, Italy, ²²University College London, UK, London, United Kingdom, ²³Sapienza University of Rome, Department of Translational and Precision Medicine Azienda Ospedaliero-Universitaria Policlinico Umberto ¹-Centro di riferimento regionale per la sclerosi sistemica, Rome, Italy, rome, Italy, ²⁴Department of Rheumatology & Immunology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland, ²⁵Université Paris Cité, Paris, France, ²⁶University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²⁷Padova University Hospital, Rheumatology Unit, Padova, Italy, padova, Italy, ²⁸Bordeaux University Hospital, Bordeaux, France, ²⁹Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ³⁰Poitiers University Hospital, Department of Internal Medicine, Poitiers, France, MIGNALOUX-BEAUVOIR, France, ³¹Rheumatology Unit, Department of Medicine and Public Health, AOU and University of Cagliari, Cagliari, Italy, ³²Waikato Hospital, Hamilton, New Zealand, ³³University of Leeds, Leeds, United Kingdom, ³⁴Spitalul Clinic Dr. Ion Cantacuzino, Bucharest, Romania, ³⁵University of Zagreb, School of Medicine, University Hospital Center Zagreb, Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, Zagreb, Croatia, zagreb, Croatia, ³⁶University of Pécs, Department Of Rheumatology And Immunology, Medical Centre, Pecs, Hungary, Pecs, Hungary, ³⁷Local de Saúde Santa Maria, Centro Académico de Medicina de Lisboa, Rheumatology Department, Lisbon, Portugal, Paris, France, ³⁸Skåne University Hospital, Department of Rheumatology, Lund, Sweden, Lund, Sweden, ³⁹University of Medicine and Pharmacy Iuliu Hatieganu Cluj, Clinica Reumatologie, Cluj-Napoca, Romania, Cluj-Napoca, Romania, ⁴⁰Stanford University, Stanford, CA, ⁴¹Fernando Fonseca Hospital, Department of Medicine IV, Systemic Immunomediated Diseases Unit, Amadora, Portugal, amadora, Portugal, ⁴²Sapienza University of Rome, Rheumatology Clinic, Rome, Italy, Rome, Italy, ⁴³University of Foggia, Department of Medical and Surgical Sciences, Rheumatology Unit, Foggia, Italy, foggia, Italy, ⁴⁴Hospital de Clinicas da Universidade Federal do Parana, Curitiba, Brazil, curitiba, Brazil, ⁴⁵Rutgers- RWJ Medical School, South Plainfield, NJ, ⁴⁶Meir Medical Center, Kfar-Saba, Israel, Kefar Sava, Israel, ⁴⁷Department of Internal Medicine, Marche University Hospital, Clinica Medica, Ancona, Italy, Ancona, Italy, ⁴⁸Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology, and Rheumatology, University Hospital Tübingen, Tuebingen, Germany, ⁴⁹UNIVERSITY OF MEDICINE AND PHARMACY CAROL DAVILA, Bucharest, Romania, ⁵⁰University Hospital Leuven, Laboratory of Tissue Homeostasis and Disease, Department of Development and Regeneration, KU Leuven, Leuven, Belgium, Leuven, Belgium
Background/Purpose: Precapillary pulmonary hypertension (PH) in systemic sclerosis (SSc) associates with severe morbidity and mortality. The prothrombotic state observed in idiopathic pulmonary arterial hypertension (PAH)…
Abstract Number: 2614 • ACR Convergence 2025
Impact of Vagus Nerve-Mediated Neuroimmune Modulation on structural joint damage using Gd-MRI RAMRIS imaging in Biologic-Experienced Patients with Rheumatoid Arthritis
Charles Peterfy, MD, PhD¹, John Tesser², Yaakov Levine³, Melissa Evangelista⁴, Vibeke Strand⁵, Michael Weinblatt⁶ and David Chernoff⁷, ¹Spire Sciences, Inc., Boca Raton, FL, ²Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ³SetPoint Medical, Valencia, CA, ⁴SetPoint Medical Corporation, Valencia, CA, ⁵Stanford University School of Medicine, Palo Alto CA, Portola Valley, CA, ⁶Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, ⁷SetPoint Medical, Sausalito, CA
Background/Purpose: Previously reported results from RESET-RA (ClinicalTrials.gov, NCT04539964) showed neuroimmune modulation via electrical stimulation of the left vagus nerve using an implantable device to treat…
Abstract Number: 0678 • ACR Convergence 2025
Targeting the plasma cell niche in systemic sclerosis: A case series about the bispecific anti-BCMAxCD3 antibody teclistamab in severe, treatment-refractory patients
Andrea-Hermina Györfi¹, Ayla Nadja Stuetz², Christina Duesing³, Laura-Marie Lahu⁴, Franca Sophie Deicher⁵, Yi-Nan Li⁶, Celine van Saan⁵, Alexandru-Emil Matei⁷, Alexander Hoelscher⁵, Peter-Martin Bruch⁸, Sarah Koziel⁸, Manuel Roehrich⁹, Mareike Cramer¹⁰, Bernhard Homey⁵, Bjoern Buehring¹¹, Alexander Kreuter¹², Aleksandar Radujkovic⁵, Claus Peter Heußel¹³, Hanns-Martin Lorenz¹⁴, Ricardo Grieshaber-Bouyer¹⁵, Georg Schett¹⁶, Jörg Distler¹⁷ and Wolfgang Merkt¹⁸, ¹Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University., Düsseldorf, Germany, ²Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University, Düsseldorf, Nordrhein-Westfalen, Germany, ³Klinik für Rheumatologie, Düsseldorf, Germany, ⁴Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University, Düsseldorf, Germany, ⁵Uniklinik Düsseldorf, Düsseldorf, Germany, ⁶University Hospital of Düsseldorf, Düsseldorf, Germany, ⁷Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, and Fraunhofer Cluster of Excellence for Immune Mediated Diseases CIMD, Frankfurt am Main, Germany, Düsseldorf, Germany, ⁸University Hospital Düsseldorf, Dusseldorf, Germany, ⁹Universitätsmedizin Mainz, Mainz, ¹⁰University Hospital Düsseldorf, Düsseldorf, Germany, ¹¹Bergisches Rheuma-Zentrum, Krankenhaus St Josef, Wuppertal, Germany, ¹²HELIOS St. Elisabeth Clinic Oberhausen, University Witten-Herdecke, Oberhausen, Germany, ¹³Thoraxklinik, University of Heidelberg, Heidelberg, ¹⁴Universitétsklinikum Heidelberg, Heidelberg, Germany, ¹⁵University Hospital Erlangen, Erlangen, Germany, ¹⁶Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ¹⁷University Hospital Duesseldorf and HHU, Duesseldorf, Germany, ¹⁸University Hospital Düsseldorf, Düsseldorf, Germany
Background/Purpose: Systemic sclerosis (SSc) possesses the highest case-related mortality of all rheumatic diseases. B cell-targeting, including CD19-targeting CAR-T cells, has shown efficacy but failed to…
Abstract Number: 2278 • ACR Convergence 2025
Neuroimmune modulation for the Treatment of Rheumatoid Arthritis: Results at 12 months from a Randomized, Sham-Controlled, Double-Blind Study
John Tesser¹, Angela Crowley², Jane Box³, Joshua June⁴, Pendleton Wickersham⁵, Guillermo Valenzuela⁶, Norman Gaylis⁷, Gordon Lam⁸, Leroy Pacheco⁹, David Ridley¹⁰, Gineth Pinto-Patarroyo¹¹, Stuart Novack¹², Melvin Churchill¹³, Minna Kohler¹⁴, Eric Lee¹⁵, Jose A Pando¹⁶, Glenn R. Parris¹⁷, Jeff Peterson¹⁸, Tina Shah¹⁹, Atul Singhal²⁰, Victoria Vuong²¹, Jeffrey Curtis²² and David Chernoff²³, ¹Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ²Illinois Bone and Joint Institute - Hinsdale Orthopaedics, Hinsdale, IL, ³DJL Clinical Research, PLLC, Charlotte, NC, ⁴Great Lakes Center of Rheumatology, Lansing, MI, ⁵Arthritis Associates PA, San Antonio, TX, ⁶Integral Rheumatology & Immunology Specialists, Plantation, FL, ⁷Arthritis & Rheumatic Disease Specialties, Aventura, FL, ⁸Arthritis and Osteoporosis Consultants of the Carolinas, Cornelius, NC, ⁹Albuquerque Ctr for Rheumatology, Albuquerque, NM, ¹⁰Saint Paul Rheumatology, Eagan, MN, ¹¹Annapolis Rheumatology, Herndon, VA, ¹²Nuvance Health network, NORWALK, CT, ¹³Arthritis Center of Nebraska, Lincoln, NE, ¹⁴Massachusetts General Hospital, Harvard Medical School, Boston, MA, ¹⁵Inland Rheumatology and Osteoporosis Medical Group, Upland, CA, ¹⁶Delaware Arthritis, Lewes, DE, ¹⁷PARRIS & ASSOCIATES, Lilburn, GA, ¹⁸Western Washington Arthritis Clinic, Seattle, WA, ¹⁹Kansas City Physician Partners, Kansas City, MO, ²⁰SouthWest Arthritis Research Group, Mesquite, TX, ²¹Long Island Regional Arthritis & Osteoporosis Care, Hicksville, NY, ²²University of Alabama at Birmingham, Birmingham, AL, ²³SetPoint Medical, Sausalito, CA
Background/Purpose: Neuroimmune modulation by electrical stimulation of the left cervical vagus nerve represents a novel treatment option for rheumatoid arthritis (RA). We present 12-month efficacy…
Abstract Number: 0565 • ACR Convergence 2025
Combination of Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Psoriatic Arthritis: A Case-Series
Andre Lucas Ribeiro¹, Virginia Carrizo Abarza², Jensen Yeung³, Khalad Maliyar³, Siddhartha Sood³, Ahmet Bagit³, Muskaan Sachdeva³, Sahil Koppikar⁴, Dafna D. Gladman⁵, Vinod Chandran⁶ and Lihi Eder⁶, ¹Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil, ²Toronto Western Hospital - University of Toronto, Toronto, ON, Canada, ³Women's College Hospital & University of Toronto, Toronto, ON, Canada, ⁴Women's College Hospital & University of Toronto, Markham, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada
Background/Purpose: Despite advances in psoriatic arthritis (PsA) treatment, remission remains elusive for many patients. This has prompted growing interest in combining biologic and targeted synthetic…
Abstract Number: 2042 • ACR Convergence 2025
Safety and Effectiveness of the Use of Combined Therapy with bDMARDS and tsDMARDs in Immune-mediated Inflammatory Diseases
Natalia Lopez Juanes¹, Carlota Ureta¹, Marta Novella-Navarro¹, Irene Monjo Henry¹, Diana Peiteado¹, Alejandro Villalba¹, Laura Nuño², Victoria Navarro-Compan³, María Sanz¹, Mª ángeles Gonzalez¹, Cristina Suarez⁴, Agustin Remesal¹, Rosa Alcobendas⁵, Clara udaondo¹, Elena Sendagorta⁵, Alejandro Balsa¹, Eugenio de Miguel¹ and Chamaida Plasencia-Rodríguez¹, ¹Hospital Universitario La Paz, Madrid, Spain, ²Hospital Universitario Puerta de Hierro, Madrid, Spain, ³Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ⁴Hospital Universitario La Paz, Madrid, Madrid, Spain, ⁵La Paz University Hospital, Madrid, Spain
Background/Purpose: The combination of biological (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) has emerged as a promising approach to improve clinical outcomes in immune-mediated inflammatory diseases…
Abstract Number: 0554 • ACR Convergence 2025
Real world experience with generic Tofacitinib in Axial Spondyloarthritis from North India
Sanjeev Kapoor¹, Babita Bondage¹, Niti Kedia¹, Mariya Patel¹ and Akanksha Kapoor², ¹Indian Spinal Injuries Centre (ISIC), New Delhi, India, ²Bharati Vidyapeeth (Deemed to be University) Medical College and Hospital, Pune, India
Background/Purpose: Axial spondyloarthritis (AxSpA) is an inflammatory condition that falls under the category of spondyloarthritis (SpA) and significantly affects quality of life, causing symptoms like…
Abstract Number: 1875 • ACR Convergence 2025
Fcγ-receptor activation by circulating immune complexes in autoimmunity and CD19.CAR-T cell therapy
Merle Freitag¹, Maren Claus², Philippe Kolb³, Valeria Falcone⁴, Ivana Andreeva¹, Norbert Blank⁵, Hanns-Martin Lorenz⁶, Georg Schett⁷ and Wolfgang Merkt⁸, ¹Uniklinik Heidelberg, Heidelberg, Germany, ²IfADo, Leibniz Institute Dortmund, Dortmund, Germany, ³INSTITUTE OF VIROLOGY Medical Center, Freiburg, Freiburg, Germany, ⁴University Medical Center, Freiburg, Freiburg, Germany, ⁵University Hospital Heidelberg, Heidelberg, Germany, ⁶Universitétsklinikum Heidelberg, Heidelberg, Germany, ⁷Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ⁸University Hospital Düsseldorf, Düsseldorf, Germany
Background/Purpose: The role of autoantibodies in systemic autoimmunity, such as connective tissue diseases (CTD), has been recently highlighted by the successful treatment with CD19-targeting CAR-T…
Abstract Number: 0877 • ACR Convergence 2025
Therapeutic Approach in Patients with Arthralgia at Risk of Progression to Psoriatic Arthritis.
Rodrigo García Salinas¹, Gisel Reyes-Jara², Felicia Almada³, Juan Arguello² and Sebastian Magri⁴, ¹Hospital Italiano La Plata, La Plata, Argentina, ²Hospital Italiano de La Plata, La Plata, Argentina, ³Hospital Italiano de La Plata, La Plara, Argentina, ⁴Hospital Italiano La Plata, Melchor Romero, Argentina
Background/Purpose: The transition from psoriasis (Pso) to psoriatic arthritis (PsA) presents an opportunity for early intervention and preventive strategies in high-risk patients with arthralgia. Objectives:…
Abstract Number: 1876 • ACR Convergence 2025
Targeting the NK cell checkpoint NKG2A promotes lung fibrosis resolution by enhancing immune clearance of senescent myofibroblasts
Wolfgang Merkt¹, Lea Rodon², Franca Sophie Deicher³, Maren Claus⁴, Rachel Lister⁵, Hongwei Han⁵, Yan Zhou⁵, Zhengwang Sun⁵, Arik Horne⁶, Ayla Nadja Stuetz⁷, Michael Kreuter⁸, nicolas kahn⁹, Marc Schneider⁹, Simon Haas¹⁰, Norbert Blank¹¹, Hanns-Martin Lorenz¹², Carsten Watzl⁴, Daniel Hübschmann¹³ and David Lagares⁵, ¹University Hospital Düsseldorf, Düsseldorf, Germany, ²University Hospital Heidelberg, Heidelberg, Hungary, ³Uniklinik Düsseldorf, Düsseldorf, Germany, ⁴IfADo, Leibniz Institute Dortmund, Dortmund, Germany, ⁵Massachusetts General Hospital and Harvard Medical School, Boston, ⁶Charite, Berlin, Berlin, ⁷Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University, Düsseldorf, Nordrhein-Westfalen, Germany, ⁸Universitätsmedizin Mainz, Mainz, ⁹Thoraxklinik, Heidelberg University, Heidelberg, Germany, ¹⁰Charite, Berlin, Berlin, Germany, ¹¹University Hospital Heidelberg, Heidelberg, Germany, ¹²Universitétsklinikum Heidelberg, Heidelberg, Germany, ¹³Heidelberg University, Berlin, Germany
Background/Purpose: A key event driving pulmonary fibrosis in interstitial lung disease (ILD) is the accumulation of pathologic senescent myofibroblasts, thought to be promoted by insufficient…
Abstract Number: 0429 • ACR Convergence 2025
Real-world experience of upadacitinib therapy in difficult-to-treat juvenile idiopathic arthritis: a case series of 24 patients
Xuemei Tang¹, Xiwen Luo², Xiya Luo¹, Mengwei Ding³, Xi Yang², Dawei Liu², Li Xu², Zhiyong Zhang², Yunfei An² and Xiaodong Zhao¹, ¹Department of Rheumatology and Immunology, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Rare Diseases in Infection and Immunity, Chongqing, China, Chongqing, China (People's Republic), ²Department of Rheumatology & Immunology, Children’s Hospital of Chongqing Medical University, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, National Clinical Research Center for Child Health and Disorders (Chongqing), Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Infection and Immunity, Chongqing, China., Chongqing, China (People's Republic), ³Big Data Center for Children’s Medical Care, Children’s Hospital of Chongqing Medical University, Chongqing, China., Chongqing, China (People's Republic)
Background/Purpose: Juvenile idiopathic arthritis (JIA) is a chronic rheumatic disease. Some patients experiencing active disease due to inadequate responses to conventional treatments. Studies have demonstrated…
Abstract Number: 1675 • ACR Convergence 2025
Neuroimmune modulation in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors (TNFi)
Guillermo Valenzuela¹, Jane Box², Angela Crowley³, Joshua June⁴, Pendleton Wickersham⁵, Jeff Peterson⁶, Michael Thakor⁷, Susan Kim⁸, Tina Shah⁹, David Chernoff¹⁰ and John Tesser¹¹, ¹Integral Rheumatology & Immunology Specialists, Plantation, FL, ²DJL Clinical Research, PLLC, Charlotte, NC, ³Illinois Bone and Joint Institute - Hinsdale Orthopaedics, Hinsdale, IL, ⁴Great Lakes Center of Rheumatology, Lansing, MI, ⁵Arthritis Associates PA, San Antonio, TX, ⁶Western Washington Arthritis Clinic, Seattle, WA, ⁷arthritis and rheumatology, Fort Collins, CO, ⁸Lehigh Valley Hospital Network, Allentown, PA, ⁹Kansas City Physician Partners, Kansas City, MO, ¹⁰SetPoint Medical, Sausalito, CA, ¹¹Arizona Arthritis & Rheumatology Associates, Phoenix, AZ
Background/Purpose: A substantial number of patients with rheumatoid arthritis (RA) experience treatment failure, incomplete response, or intolerance to TNFis (TNFi-IR). Neuroimmune modulation using an implantable…
Abstract Number: 0370 • ACR Convergence 2025
Patient Preferences for Treatments of Rheumatoid Arthritis: A Discrete Choice Experiment Evaluating Preference for Advanced Drug Therapies and Neuroimmune Modulation Device
Jeffrey Curtis¹, Joshua Baker², Shilpa Venkatachalam³, Sherry Danese⁴, Julie Ulloa⁵ and Ankit Shah⁶, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Pennsylvania, Philadelphia, PA, ³Global Healthy Living Foundation, New York, NY, ⁴OutcomesInsights, Calabasas, CA, ⁵OutcomesInsights, Calabasas, ⁶SetPoint Medical, Valencia, CA
Background/Purpose: Despite broadening treatment options for RA, several challenges and unmet needs remain. The 2021 ACR guideline for the treatment of RA marked a significant…
Abstract Number: 1600 • ACR Convergence 2025
Real-world clinical effectiveness of Benralizumab for Eosinophilic Granulomatosis with Polyangiitis: a National multicenter study
Fabricio Benavides Villanueva¹, Andrea Tristan-Alonso², Carlos Martinez-Rivera³, Alicia Padilla-Galo⁴, Marina Blanco-Aparicio⁵ and Ricardo Blanco⁶, ¹Division of Rheumatology, Hospital Universitario Marques de Valdecilla, IDIVAL, Immunopathology Group,Santander, Spain, Santander, Spain, ²Division of Pneumology, Hospital Universitario Puerta del Hierro, Madrid, Spain, Majadahonda, Madrid, Spain, ³Division of Pneumology, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, Barcelona, Catalonia, Spain, ⁴Division of Pneumology, Hospital Universitario Virgen de la Victoria, Málaga, Spain, Malaga, Andalucia, Spain, ⁵Division of Pneumology, Hospital Universitario A Coruña, A Coruña, Spain, A coruña, Galicia, Spain, ⁶Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Benralizumab is approved for eosinophil-driven conditions, like eosinophilic asthma. Recently, the European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA) authorized its…

1
2
3
…
7
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].